Analysis of changes in the new edition of the European Clinical Guidelines on urticaria 2020 revision
- Authors: Danilycheva I.V.1, Shulzhenko A.E.1
-
Affiliations:
- National Research Center ― Institute of Immunology Federal Medical-Biological Agency of Russia
- Issue: Vol 19, No 1 (2022)
- Pages: 142-151
- Section: Clinical practice guidelines
- URL: https://journals.rcsi.science/raj/article/view/121727
- DOI: https://doi.org/10.36691/RJA1523
- ID: 121727
Cite item
Full Text
Abstract
The current European Clinical Guidelines on urticaria have been initiated by the European Academy of Allergy and Clinical Immunology (EAACI), Dermatology Section of the EAACI, Global Allergy and Asthma European Network, Urticaria and Angioedema Centers of Reference and Excellence, European Dermatology Forum (EuroGuiDerm), Asia Pacific Association of Allergy, and Asthma and Clinical immunology (Asia Pacific Association of Allergy, Asthma and Clinical Immunology). These guidelines have been adopted by the European Union of Medical Specialists. The purpose of the manual is to define and categorize urticaria (with the focus on chronic urticaria), causes, triggers, comorbidities, and burden on patients and society to present the latest advances in the diagnosis and management of patients with chronic urticaria.
This study analyzes the changes in the new edition of the European Clinical Guidelines on urticaria 2020 revision. The changes relate to expanding the goals of the diagnostic examination of patients and quantity of mandatory examinations. The level of persuasiveness of recommendations for assessing the activity and control of chronic spontaneous urticaria and the impact of the disease on the quality of life of patients has been increased. Treatment should correspond to the level of control of the disease and change according to the principle “assess–act–adjust.” In the new edition, the scheme of the stepwise approach to the treatment of urticaria has been changed: the first line is combined with the second. A significant change is the recommendation to increase the dose of omalizumab to 600 mg and reduce the interval to 2 weeks in patients with insufficient response.
The purpose of creating clinical guidelines is to provide information support for physicians to make decisions that improve the quality of medical care for the patient with a particular disease/condition/syndrome, taking into account the latest clinical data and principles of evidence-based medicine.
Full Text
##article.viewOnOriginalSite##About the authors
Inna V. Danilycheva
National Research Center ― Institute of Immunology Federal Medical-Biological Agency of Russia
Author for correspondence.
Email: ivdanilycheva@mail.ru
ORCID iD: 0000-0002-8279-2173
SPIN-code: 4547-3948
MD, Cand. Sci. (Med.)
Russian Federation, 24, Kashyrskoe shosse, Moscow, 115522Andrey E. Shulzhenko
National Research Center ― Institute of Immunology Federal Medical-Biological Agency of Russia
Email: shulzhenko_ae@mail.ru
ORCID iD: 0000-0003-0268-9350
SPIN-code: 4584-4915
MD, Dr. Sci. (Med.), Professor
Russian Federation, 24, Kashyrskoe shosse, Moscow, 115522References
- Zuberbier T, Greaves MW, Juhlin L, et al. Management of urticaria: a consensus report. J Investig Dermatol Symp Proc. 2001;6(2): 128–231. doi: 10.1046/j.0022-202x.2001.00023.x
- Zuberbier T, Latiff AH, Abuzakouk M, et al. The international EAACI/GA²LEN/EuroGuiDerm/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria. Allergy. 2022;77(3):734–766. doi: 10.1111/all.15090
- Andreeva NS, Rebrova OYu, Zorin NA, et al. Systems for assessing the reliability of scientific evidence and the credibility of recommendations: comparative characteristics and prospects for unification. Medical Technologies: Assessment and Choice. 2012;(4):10–24.
- Zuberbier T, Aberer W, Asero R, et al. The EAACI/GA²LEN/EDF/WAO Guideline for the definition, classification, diagnosis, and management of urticaria: the 2013 revision and update. Allergy. 2014;69(7):868–887. doi: 10.1111/all.12313
- Kolkhir P, Kovalkova E, Chernov A, et al. Autoimmune chronic spontaneous urticaria detection with IgG anti-TPO and total IgE. J Allergy Clin Immunol Pract. 2021;9(11):4138–4146.e8. doi: 10.1016/j.jaip.2021.07.043
- Türk M, Carneiro-Leão L, Kolkhir P, et al. How to treat patients with chronic spontaneous urticaria with omalizumab: questions and answers. J Allergy Clin Immunol Pract. 2020;8(1):113–124. doi: 10.1016/j.jaip.2019.07.021
Supplementary files
